0 01/04/2024 31/03/2025 2025-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2024-04-01 Sage Accounts Production 23.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 09304650 2024-04-01 2025-03-31 09304650 2025-03-31 09304650 2024-03-31 09304650 2023-04-01 2024-03-31 09304650 2024-03-31 09304650 2023-03-31 09304650 bus:RegisteredOffice 2024-04-01 2025-03-31 09304650 bus:Director3 2024-04-01 2025-03-31 09304650 bus:Director4 2024-04-01 2025-03-31 09304650 core:WithinOneYear 2025-03-31 09304650 core:WithinOneYear 2024-03-31 09304650 core:ShareCapital 2025-03-31 09304650 core:ShareCapital 2024-03-31 09304650 core:RetainedEarningsAccumulatedLosses 2025-03-31 09304650 core:RetainedEarningsAccumulatedLosses 2024-03-31 09304650 bus:SmallEntities 2024-04-01 2025-03-31 09304650 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 09304650 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 09304650 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 09304650 bus:FullAccounts 2024-04-01 2025-03-31
Company registration number: 09304650
Asterisk Lifesciences Ltd
Unaudited filleted financial statements
31 March 2025
Asterisk Lifesciences Ltd
Contents
Directors and other information
Statement of financial position
Notes to the financial statements
Asterisk Lifesciences Ltd
Directors and other information
Directors
Dr Vibha Gagan Sharma
Mr G H Sharma
Company number 09304650
Registered office Suite 14
45 St Mary's Road
Ealing
W5 5RG
Asterisk Lifesciences Ltd
Statement of financial position
31 March 2025
2025 2024
Note £ £ £ £
Current assets
Debtors 3 24,579 25,134
Cash at bank and in hand - 6,471
_______ _______
24,579 31,605
Creditors: amounts falling due
within one year 5 ( 37,795) ( 34,020)
_______ _______
Net current liabilities ( 13,216) ( 2,415)
_______ _______
Total assets less current liabilities ( 13,216) ( 2,415)
_______ _______
Net liabilities ( 13,216) ( 2,415)
_______ _______
Capital and reserves
Called up share capital 100 100
Profit and loss account ( 13,316) ( 2,515)
_______ _______
Shareholders deficit ( 13,216) ( 2,415)
_______ _______
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 23 June 2025 , and are signed on behalf of the board by:
Dr Vibha Gagan Sharma Mr G H Sharma
Director Director
Asterisk Lifesciences Ltd
Notes to the financial statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England & Wales. The address of the registered office is Suite 14, 45 St Mary's Road, Ealing, W5 5RG.
2. Accounting policies
Accounting convention
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ('FRS 102') and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a fair view. The financial statements are prepared in Sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £. The financial statements have been prepared under historical cost convention. The principal accounting policies adopted are set out below.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
3. Debtors
2025 2024
£ £
Amounts owed by group undertakings and undertakings in which the company has a participating interest 24,579 25,134
_______ _______
4.
Included in debtors is amount of £24,579 (2024: £25,134) owed by related company Bliss GVS International Pte Ltd, Singapore.
5. Creditors: amounts falling due within one year
2025 2024
£ £
Amounts owed to group undertakings and undertakings in which the company has a participating interest 25,075 24,180
Other creditors 12,720 9,840
_______ _______
37,795 34,020
_______ _______
6.
Included in creditors is amount of £25,075 (2024: £24,180) owed to the holding company Bliss GVS Pharma Limited.
7. Related party transactions
During the year the company entered into the following transactions with related parties:
Transaction value Balance owed by/(owed to)
2025 2024 2025 2024
£ £ £ £
Bliss GVS Pharma Limited ( 895) 2,945 ( 25,075) ( 24,180)
Bliss GVS International Pte Ltd, Singapoure ( 555) 25,134 24,579 25,134
_______ _______ _______ _______
Bliss GVS International Pte Ltd, Singapore is a wholly owned subsidiary of Bliss GVS Pharma Limited, a company incorporated in India. .
8. Controlling party
The company is wholly owned by Bliss GVS Pharma Limited incorporated in India. The directors of the company are also directors of the holding company.